Male smokers at increased risk for osteoporosis, fractures
the ONA take:
According to a new study published online in the journal Annals of the American Thoracic Society, researchers have found that among middle-aged to elderly tobacco smokers, men were more likely than women to have osteoporosis and vertebral fractures.
For the large study, researchers from National Jewish Health and other institutions analyzed data from 3,321 current and ex-smokers aged 45 to 80 years old. Patients were eligible if they had a minimum 10 pack-year smoking history.
Results showed that 11% of participants had normal bone density, 31% had intermediate bone density, and 58% had low bone density. In addition, 37% had one or more vertebral fractures.
Researchers found that of those with low bone density and vertebral fractures, 55% and 60%, respectively, were men. Results also showed that 84% of participants of both genders with severe chronic obstructive pulmonary disease (COPD) had low-bone density.
Each additional pack-year of tobacco smoking was associated with a 0.4% increased risk of low bone density. The findings suggest that past and current smokers of both genders should be screened for osteoporosis.
Among middle-aged to elderly tobacco smokers, men were more likely than women to have osteoporosis and vertebral fractures.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
- Radiotherapy is Essential in Treating Brain Tumors But Associated With Significant Adverse Events
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|